{"id":"nab-paclitaxel","rwe":[{"pmid":"41900865","year":"2026","title":"Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"41899178","year":"2026","title":"Chemotherapy for Older Adults with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41896491","year":"2026","title":"Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study.","finding":"","journal":"Journal of cancer research and clinical oncology","studyType":"Clinical Study"},{"pmid":"41892321","year":"2026","title":"Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer.","finding":"","journal":"Cells","studyType":"Clinical Study"},{"pmid":"41891402","year":"2026","title":"Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring.","finding":"","journal":"Cancer discovery","studyType":"Clinical Study"}],"tags":[{"label":"Microtubule Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Tubulin beta-3 chain","category":"target"},{"label":"TUBB3","category":"gene"},{"label":"TUBB","category":"gene"},{"label":"TUBB1","category":"gene"},{"label":"L01CD01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Carcinoma of breast","category":"indication"},{"label":"Carcinoma of fallopian tube","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Kaposi's sarcoma","category":"indication"},{"label":"Malignant tumor of cervix","category":"indication"},{"label":"Malignant tumor of ovary","category":"indication"},{"label":"Hq Spclt Pharma","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Antimitotic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Phytogenic","category":"pharmacology"},{"label":"Tubulin Modulators","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":3162.161,"date":"","count":2867,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 2,867 times (LLR=3162)"},{"llr":3136.121,"date":"","count":4038,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 4,038 times (LLR=3136)"},{"llr":2796.109,"date":"","count":2893,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 2,893 times (LLR=2796)"},{"llr":2243.822,"date":"","count":2858,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 2,858 times (LLR=2244)"},{"llr":2063.329,"date":"","count":2847,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 2,847 times (LLR=2063)"},{"llr":1518.387,"date":"","count":3685,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 3,685 times (LLR=1518)"},{"llr":1474.021,"date":"","count":1058,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 1,058 times (LLR=1474)"},{"llr":1378.114,"date":"","count":944,"signal":"Metastases to liver","source":"DrugCentral FAERS","actionTaken":"Reported 944 times (LLR=1378)"},{"llr":1210.745,"date":"","count":831,"signal":"Metastases to bone","source":"DrugCentral FAERS","actionTaken":"Reported 831 times (LLR=1211)"},{"llr":1180.668,"date":"","count":1363,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 1,363 times (LLR=1181)"},{"llr":1122.342,"date":"","count":1336,"signal":"Flushing","source":"DrugCentral FAERS","actionTaken":"Reported 1,336 times (LLR=1122)"},{"llr":1051.615,"date":"","count":2095,"signal":"Erythema","source":"DrugCentral FAERS","actionTaken":"Reported 2,095 times (LLR=1052)"},{"llr":1017.279,"date":"","count":2329,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 2,329 times (LLR=1017)"},{"llr":1010.634,"date":"","count":1480,"signal":"Leukopenia","source":"DrugCentral FAERS","actionTaken":"Reported 1,480 times (LLR=1011)"},{"llr":950.14,"date":"","count":557,"signal":"Peripheral sensory neuropathy","source":"DrugCentral FAERS","actionTaken":"Reported 557 times (LLR=950)"}],"commonSideEffects":[],"contraindications":["Acute cerebrovascular insufficiency","Acute exacerbation of asthma","Acute infectious disease","Acute nephropathy","Anaphylaxis","Anemia","Asthma","Bone marrow depression","Bradycardia","Breastfeeding (mother)","Bronchospasm","Cardiogenic shock","Chronic heart failure","Complete atrioventricular block","Conduction disorder of the heart","Decompensated cardiac failure","Depressive disorder","Diabetes mellitus","Disease of liver","Heart block","Hyperbilirubinemia","Hypoglycemic disorder","Kidney disease","Liver function tests abnormal","Low blood pressure"],"specialPopulations":{"Lactation":"There are no data on the presence of paclitaxel in human milk, or its effect on the breastfed child or on milk production. In animal studies, paclitaxel and/or its metabolites were excreted into the milk of lactating rats. Because of the potential for serious adverse reactions in breastfed child from paclitaxel protein-bound particles for injectable suspension (albumin-bound), advise lactating women not to breastfeed during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound).","Pregnancy":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm when administered to pregnant woman. Advise females of reproductive potential of the potential risk to fetus. The background rate of major birth defects and miscarriage is unknown for the indicated population. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Pregnancy Category D.","Geriatric use":"Of 2,228 patients who received paclitaxel in clinical studies evaluating its safety and effectiveness in the treatment of advanced ovarian cancer, breast carcinoma, or NSCLC, and 1,570 patients who were randomized to receive paclitaxel in the adjuvant breast cancer study, 649 patients (17%) were 65 years or older and 49 patients (1%) were 75 years or older. In most studies, severe myelosuppression was more frequent in elderly patients; in some studies, severe neuropathy was more ","Paediatric use":"The safety and effectiveness of paclitaxel in pediatric patients have not been established. There have been reports of central nervous system (CNS) toxicity (rarely associated with death) in clinical trial in pediatric patients in which paclitaxel was infused intravenously over hours at doses ranging from 350 mg/m2 to 420 mg/m2."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2034-07-12","territory":"US","patentNumber":"9511046*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2034-01-12","territory":"US","patentNumber":"9511046"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"9393318*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-09-04","territory":"US","patentNumber":"9597409*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-03-04","territory":"US","patentNumber":"9393318"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-03-04","territory":"US","patentNumber":"9597409"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-02-13","territory":"US","patentNumber":"8034375*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-21","territory":"US","patentNumber":"7758891*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-21","territory":"US","patentNumber":"8268348*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-21","territory":"US","patentNumber":"9101543*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-13","territory":"US","patentNumber":"8034375"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-02-21","territory":"US","patentNumber":"7758891"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-02-21","territory":"US","patentNumber":"8268348"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-02-21","territory":"US","patentNumber":"9101543"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-04-27","territory":"US","patentNumber":"7820788*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-10-27","territory":"US","patentNumber":"7820788"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-06-09","territory":"US","patentNumber":"7923536*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-06-09","territory":"US","patentNumber":"8138229*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-06-09","territory":"US","patentNumber":"8314156*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-12-09","territory":"US","patentNumber":"7923536"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-12-09","territory":"US","patentNumber":"8138229"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-12-09","territory":"US","patentNumber":"8314156"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=nab-paclitaxel","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:45:11.833906+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:45:11.833843+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Nab-Paclitaxel","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:45:20.513305+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:45:18.813677+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:45:11.906650+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nab-paclitaxel","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:45:19.187100+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4303645/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:45:20.153276+00:00"}},"allNames":"taxol","offLabel":[],"synonyms":["paclitaxel","(-)-Paclitaxel","abraxane","capxol","cyclopax","ebetaxel","genaxol","mitotax","padexol","plaxicel","taxol","Taxol A","Tocosol Paclitaxel","nabpaclitaxel","ABI-007","nab-paclitaxel"],"timeline":[{"date":"1992-12-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hq Spclt Pharma)"},{"date":"2019-05-10","type":"positive","source":"DrugCentral","milestone":"EMA approval (Teva Bv)"},{"date":"2019-09-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Taiho Pharmaceutical Co., Ltd.)"}],"aiSummary":"Taxol, also known as paclitaxel, is a small molecule used to treat various cancers, including breast carcinoma, pancreatic cancer, and pancreatic ductal adenocarcinoma. It works by preventing the normal breakdown of microtubules during cell division, ultimately killing cancer cells.","brandName":"Taxol","ecosystem":[{"indication":"Carcinoma of breast","otherDrugs":[{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"epirubicin","slug":"epirubicin","company":"Pfizer Inc"}],"globalPrevalence":160000000},{"indication":"Carcinoma of fallopian tube","otherDrugs":[],"globalPrevalence":null},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Kaposi's sarcoma","otherDrugs":[{"name":"daunorubicin","slug":"daunorubicin","company":""},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"vinblastine","slug":"vinblastine","company":""}],"globalPrevalence":null},{"indication":"Malignant tumor of cervix","otherDrugs":[{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"cemiplimab","slug":"cemiplimab","company":"Regeneron Pharmaceuticals "},{"name":"topotecan","slug":"topotecan","company":"Novartis Pharms Corp"}],"globalPrevalence":null},{"indication":"Malignant tumor of ovary","otherDrugs":[{"name":"altretamine","slug":"altretamine","company":"Eisai Inc"},{"name":"carboplatin","slug":"carboplatin","company":""},{"name":"cisplatin","slug":"cisplatin","company":"Hq Spclt Pharma"},{"name":"doxorubicin","slug":"doxorubicin","company":""}],"globalPrevalence":null},{"indication":"Malignant tumor of peritoneum","otherDrugs":[{"name":"bevacizumab","slug":"bevacizumab","company":"Genentech"},{"name":"niraparib","slug":"niraparib","company":"Tesaro Inc"},{"name":"olaparib","slug":"olaparib","company":"Astrazeneca Pharms"}],"globalPrevalence":null},{"indication":"Metastatic Breast Carcinoma","otherDrugs":[{"name":"capecitabine","slug":"capecitabine","company":"Hoffmann La Roche"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"eribulin","slug":"eribulin","company":"Eisai Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Tubulin beta-3 chain","novelty":"Follow-on","targets":[{"gene":"TUBB3","source":"DrugCentral","target":"Tubulin beta-3 chain","protein":"Tubulin beta-3 chain"},{"gene":"TUBB","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta chain"},{"gene":"TUBB1","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-1 chain"},{"gene":"TUBB2A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2A chain"},{"gene":"TUBB2B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2B chain"},{"gene":"TUBB4A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4A chain"},{"gene":"TUBB4B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4B chain"},{"gene":"TUBB6","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-6 chain"},{"gene":"TUBB8","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-8 chain"},{"gene":"OPRD1","source":"DrugCentral","target":"Delta-type opioid receptor","protein":"Delta-type opioid receptor"}],"modality":"Small Molecule","drugClass":"Microtubule Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Taxol binds to the beta subunit of tubulin, stabilizing microtubules and preventing their dynamic instability, which is essential for cell division. This leads to cell cycle arrest and apoptosis in cancer cells, making Taxol an effective chemotherapeutic agent."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Protein-bound_paclitaxel","title":"Protein-bound paclitaxel","extract":"Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division. In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease \"metastatic adenocarcinoma of the pancreas\".","wiki_society_and_culture":"==Society and culture==\nAbraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs. Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.\n\nIn 2010, Abraxis was acquired by Celgene, which now markets Abraxane. Total revenue from the sales of Abraxane for 2009 were $314.5 million.  In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer. In 2014, Abraxane's sales were $848 million, 31 percent year-over-year increase. In 2019 Bristol Meyers Squibb acquired Celgene for $74 billion dollars, and thus acquired Abraxis Bioscience and the rights to manufacture and market Abraxane. \n\nThe UK's National Institute for Health and Care Excellence (NICE) announced in 2015, that it would not support the routine use of protein-bound paclitaxel in advanced pancreatic cancer on the NHS. However, this decision was changed in September 2017. It has continued to be reimbursed in England since then, despite questionable real world effectiveness."},"commercial":{"launchDate":"1992","revenueYear":2025,"_launchSource":"DrugCentral (FDA 1992-12-29, HQ SPCLT PHARMA)","annualRevenue":368,"revenueSource":"SEC 8-K Bristol-Myers Squibb (2026-02-05)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:02.206315","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2044","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=nab-paclitaxel","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nab-paclitaxel","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Protein-bound_paclitaxel","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:18:53.484536","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:45:21.788062+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"docetaxel","drugSlug":"docetaxel","fdaApproval":"1996-05-14","patentExpiry":"Sep 30, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cabazitaxel","drugSlug":"cabazitaxel","fdaApproval":"2010-06-17","patentExpiry":"Oct 27, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"nab-paclitaxel","indications":{"approved":[{"name":"Carcinoma of breast","source":"DrugCentral","snomedId":254838004,"regulator":"FDA","eligibility":{"adjuvant therapy":"node-positive breast cancer, administered sequentially to standard doxorubicin-containing combination chemotherapy","first-line therapy":"node-positive breast cancer, administered sequentially to standard doxorubicin-containing combination chemotherapy","metastatic disease":"prior therapy should have included an anthracycline unless clinically contraindicated"},"usPrevalence":null,"globalPrevalence":160000000,"prevalenceMethod":"curated","prevalenceSource":"Expert Rev Clin Pharmacol, 2019 (PMID:31287333)"},{"name":"Carcinoma of fallopian tube","source":"DrugCentral","snomedId":276870001,"regulator":"FDA","eligibility":{"advanced carcinoma":"no specific eligibility criteria mentioned"}},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"}},{"name":"Kaposi's sarcoma","source":"DrugCentral","snomedId":109385007,"regulator":"FDA","eligibility":{"second-line treatment":"AIDS-related"}},{"name":"Malignant tumor of cervix","source":"DrugCentral","snomedId":363354003,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"}},{"name":"Malignant tumor of ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA","eligibility":{"advanced carcinoma":"no specific eligibility criteria mentioned"}},{"name":"Malignant tumor of peritoneum","source":"DrugCentral","snomedId":363492001,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"}},{"name":"Metastatic Breast Carcinoma","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":{"prior therapy":"prior therapy should have included an anthracycline unless clinically contraindicated"}},{"name":"Non-small cell lung cancer","source":"DrugCentral","snomedId":254637007,"regulator":"FDA","eligibility":{"first-line treatment":"not candidates for potentially curative surgery and/or radiation therapy"},"usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Ocular hypertension","source":"DrugCentral","snomedId":4210003,"regulator":"FDA","eligibility":{"no indication":"no specific eligibility criteria mentioned"},"usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Open-angle glaucoma","source":"DrugCentral","snomedId":84494001,"regulator":"FDA"},{"name":"Secondary malignant neoplasm of pancreas","source":"DrugCentral","snomedId":94459006,"regulator":"FDA"}],"offLabel":[{"name":"Aphakic glaucoma","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Endometrial carcinoma","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":8,"evidenceLevel":"emerging"},{"name":"Malignant glaucoma","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Malignant tumor of head and/or neck","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":510941,"evidenceLevel":"strong"},{"name":"Malignant tumor of testis","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Malignant tumor of urinary bladder","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":22,"evidenceLevel":"moderate"},{"name":"Neoplasm of esophagus","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":66,"evidenceLevel":"strong"},{"name":"Secondary glaucoma","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Small cell carcinoma of lung","source":"DrugCentral","drugName":"nab-paclitaxel","evidenceCount":323,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"docetaxel","brandName":"docetaxel","genericName":"docetaxel","approvalYear":"1996","relationship":"same-class"},{"drugId":"cabazitaxel","brandName":"cabazitaxel","genericName":"cabazitaxel","approvalYear":"2010","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":["Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm"],"enrollment":115,"completionDate":"2026-06-01"},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":["Triple Negative Breast Neoplasms"],"enrollment":1000,"completionDate":"2030-05-18"},{"nctId":"NCT07493993","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-06-01","conditions":["ESCC"],"enrollment":26,"completionDate":"2030-12-31"},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Invasive Breast Carcinoma","Metastatic Triple-Negative Breast Carcinoma"],"enrollment":70,"completionDate":"2026-12-30"},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":["Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma"],"enrollment":94,"completionDate":"2030-12"},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":["Non-small Cell Lung Cancer","NSCLC"],"enrollment":851,"completionDate":"2031-02-12"},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":["Advanced or Metastatic Solid Tumors"],"enrollment":72,"completionDate":"2026-05-19"},{"nctId":"NCT07259317","phase":"PHASE2","title":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2026-01-27","conditions":["Adenocarcinoma","Carcinoma, Pancreatic Ductal"],"enrollment":60,"completionDate":"2027-07"},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":["Breast Neoplasms"],"enrollment":1200,"completionDate":"2031-04-12"},{"nctId":"NCT05685602","phase":"PHASE1","title":"CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-12","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Ductal Adenocarcinoma"],"enrollment":43,"completionDate":"2026-04-30"},{"nctId":"NCT06561685","phase":"PHASE1","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-19","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor","Non-small Cell Lung Cancer","SMARCA4-Deficient Tumor"],"enrollment":340,"completionDate":"2027-10"},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":["Triple Negative Breast Neoplasms"],"enrollment":137,"completionDate":"2026-02-05"},{"nctId":"NCT05982522","phase":"PHASE1,PHASE2","title":"IN10018 Combination Therapy in Previously-treated Solid Tumors","status":"WITHDRAWN","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2025-08-13","conditions":["Solid Tumor"],"enrollment":0,"completionDate":"2026-12-31"},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":["Breast Neoplasms"],"enrollment":1000,"completionDate":"2033-07-14"},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":["Metastatic Lung Non-Squamous Non-Small Cell Carcinoma","Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":117,"completionDate":"2026-12-31"},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":["Advanced Lung Non-Small Cell Carcinoma","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8"],"enrollment":304,"completionDate":"2026-06-01"},{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":["Solid Tumors"],"enrollment":260,"completionDate":"2032-05-20"},{"nctId":"NCT05825066","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-08-01","conditions":["Pancreas Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma"],"enrollment":64,"completionDate":"2028-07"},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":["Triple-Negative Breast Cancer"],"enrollment":134,"completionDate":"2026-11-01"},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":["Breast Neoplasms"],"enrollment":558,"completionDate":"2030-09"},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":["Squamous Non-small Cell Lung Cancer"],"enrollment":180,"completionDate":"2031-05-06"},{"nctId":"NCT06926868","phase":"PHASE2,PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":["Breast Neoplasms"],"enrollment":500,"completionDate":"2030-05-15"},{"nctId":"NCT07076121","phase":"PHASE2,PHASE3","title":"A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-10-23","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":470,"completionDate":"2029-05-03"},{"nctId":"NCT07491445","phase":"PHASE3","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2026-03-09","conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma"],"enrollment":900,"completionDate":"2029-03"},{"nctId":"NCT07490002","phase":"PHASE2","title":"Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-04-06","conditions":["Esophageal Squamous Carcinoma"],"enrollment":33,"completionDate":"2030-11-30"},{"nctId":"NCT06917079","phase":"PHASE1","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2025-03-31","conditions":["Non-Small Cell Lung Cancer","NSCLC","PDAC - Pancreatic Ductal Adenocarcinoma","CRC (Colorectal Cancer)","Metastatic Non-Small Lung Cell Cancer","Metastatic Colorectal Cancer (CRC)","KRAS G12A","KRAS G12C","KRAS G12D","KRAS G12S","KRAS G12V","Metastatic Pancreatic Ductal Adenocarcinoma","Advanced Lung Carcinoma","Solid Tumor, Adult"],"enrollment":387,"completionDate":"2029-09"},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8"],"enrollment":2175,"completionDate":"2038-12-31"},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":["Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":176,"completionDate":"2026-12-31"},{"nctId":"NCT07488884","phase":"PHASE1","title":"Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-03-01","conditions":["Pancreatic Cancer Resectable","Pancreatic Cancer"],"enrollment":30,"completionDate":"2029-06-01"},{"nctId":"NCT04894643","phase":"NA","title":"Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2020-09-14","conditions":["Pancreatic Cancer","Proton Therapy"],"enrollment":10,"completionDate":"2027-12-31"},{"nctId":"NCT04253964","phase":"PHASE2","title":"Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":["Nonsmall Cell Lung Cancer","Performance Status"],"enrollment":105,"completionDate":"2026-09"},{"nctId":"NCT04143711","phase":"PHASE1,PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":["Solid Tumor, Adult"],"enrollment":270,"completionDate":"2025-12-05"},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":41,"completionDate":"2027-06-20"},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":["Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer","High-grade Serous Ovarian Cancer","Endometrioid Ovarian Cancer","Ovarian Clear Cell Carcinoma"],"enrollment":186,"completionDate":"2026-10"},{"nctId":"NCT07283705","phase":"PHASE2","title":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-18","conditions":["Phase 2 Study","BMS-986504","MTAP-deleted Pancreatic Cancer"],"enrollment":60,"completionDate":"2031-10-01"},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Triple-Negative Breast Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Unresectable Triple-Negative Breast Carcinoma"],"enrollment":57,"completionDate":"2027-03-31"},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":["Non-small Cell Lung Cancer","Metastatic Non-small Cell Lung Cancer"],"enrollment":400,"completionDate":"2026-10"},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":["Lung Cancer","Advanced or Metastatic Non-Small-Cell Lung Cancer","Resectable Non-Small-Cell Lung Cancer"],"enrollment":270,"completionDate":"2029-09"},{"nctId":"NCT07063745","phase":"PHASE2,PHASE3","title":"A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-01-02","conditions":["Metastatic Non-small Cell Lung Cancer With MTAP Deletion"],"enrollment":590,"completionDate":"2031-08-12"},{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":["Nasopharyngeal Cancinoma (NPC)"],"enrollment":243,"completionDate":"2031-03-12"},{"nctId":"NCT07223047","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-25","conditions":["Advanced Solid Malignancies","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)"],"enrollment":252,"completionDate":"2028-10-13"},{"nctId":"NCT05852691","phase":"PHASE2","title":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-07-18","conditions":["Breast Cancer"],"enrollment":83,"completionDate":"2026-10-31"},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":["HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis"],"enrollment":184,"completionDate":"2030-12-30"},{"nctId":"NCT05601323","phase":"NA","title":"A Study of Suizenji in Patients With Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SONIRE Therapeutics Inc.","startDate":"2023-01-31","conditions":["Unresectable Pancreatic Cancer"],"enrollment":90,"completionDate":"2027-05-31"},{"nctId":"NCT05227664","phase":"PHASE2","title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-03-23","conditions":["Metastatic Triple-negative Breast Cancer","Locally Advanced Triple-negative Breast Cancer"],"enrollment":120,"completionDate":"2027-06-30"},{"nctId":"NCT06767527","phase":"PHASE3","title":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-02-07","conditions":["Triple-Negative Breast Cancer (TNBC)"],"enrollment":416,"completionDate":"2028-12"},{"nctId":"NCT04083599","phase":"PHASE1,PHASE2","title":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2019-09-17","conditions":["Malignant Solid Tumor","Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Melanoma","Head and Neck Squamous Cell Carcinoma (HNSCC)","Pancreatic Ductal Adenocarcinoma (PDAC)"],"enrollment":350,"completionDate":"2026-11"},{"nctId":"NCT03424005","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":["Metastatic Breast Cancer"],"enrollment":792,"completionDate":"2030-09-30"},{"nctId":"NCT07475234","phase":"PHASE1,PHASE2","title":"Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Xiuchao Wang","startDate":"2026-03","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":30,"completionDate":"2028-12"},{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":["Gastric Cancer","Second-line Therapy"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT06445062","phase":"PHASE1,PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-05-24","conditions":["Colorectal Cancer","CRC","Pancreatic Ductal Adenocarcinoma","PDAC","Gastrointestinal Cancer","Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":1130,"completionDate":"2027-07-15"},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":25,"completionDate":"2028-01-31"},{"nctId":"NCT07454031","phase":"PHASE1","title":"Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":["Peritoneal (Metastatic) Cancer"],"enrollment":22,"completionDate":"2027-12-31"},{"nctId":"NCT05285358","phase":"PHASE1","title":"Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-09-19","conditions":["Distal Bile Duct Adenocarcinoma","Gallbladder Carcinoma","Intrahepatic Cholangiocarcinoma","Metastatic Malignant Neoplasm in the Peritoneum","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Stage IVB Gallbladder Cancer AJCC v8"],"enrollment":12,"completionDate":"2028-10-11"},{"nctId":"NCT05742269","phase":"","title":"Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Karolinska University Hospital","startDate":"2023-07-01","conditions":["Metastatic Triple-Negative Breast Carcinoma"],"enrollment":3,"completionDate":"2026-03-11"},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":30,"completionDate":"2029-03-11"},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":["Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer","Colorectal Cancer","Advanced Solid Tumor","Metastatic Solid Tumor"],"enrollment":750,"completionDate":"2030-01"},{"nctId":"NCT03816163","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-03-15","conditions":["Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"enrollment":393,"completionDate":"2026-08-31"},{"nctId":"NCT07463313","phase":"PHASE2,PHASE3","title":"6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":["Thymoma and Thymic Carcinoma"],"enrollment":116,"completionDate":"2032-03"},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":["Breast Neoplasms"],"enrollment":340,"completionDate":"2027-12-18"},{"nctId":"NCT04205812","phase":"PHASE3","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2020-09-11","conditions":["Metastatic Squamous Non-Small Cell Lung Cancer","Metastatic Nonsquamous Non-Small Cell Lung Cancer"],"enrollment":583,"completionDate":"2026-08-28"},{"nctId":"NCT05689671","phase":"PHASE4","title":"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nikolaj Frost MD","startDate":"2023-12-06","conditions":["Non-Small Cell Lung Cancer Metastatic"],"enrollment":136,"completionDate":"2026-10"},{"nctId":"NCT07457346","phase":"PHASE2","title":"A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":["Head and Neck Cancer Squamous Cell Carcinoma"],"enrollment":76,"completionDate":"2030-08-30"},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":["Metastatic Adenocarcinoma of the Pancreas"],"enrollment":770,"completionDate":"2025-02-18"},{"nctId":"NCT07020221","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":["Pancreatic Ductal Adenocarcinoma","Non Small Cell Lung Cancer","Colorectal Cancer","Solid Tumor, Adult","G12D Mutated KRAS"],"enrollment":295,"completionDate":"2028-12"},{"nctId":"NCT06646055","phase":"PHASE1,PHASE2","title":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2025-01-21","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":110,"completionDate":"2027-12-30"},{"nctId":"NCT07191418","phase":"NA","title":"Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors","status":"NOT_YET_RECRUITING","sponsor":"Roberto Valente","startDate":"2026-03","conditions":["Pancreatic Cancer Metastatic to Liver"],"enrollment":178,"completionDate":"2027-09"},{"nctId":"NCT07454018","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-01","conditions":["Recurrent Ovarian Cancer","Platinum-sensitive Ovarian Cancer"],"enrollment":45,"completionDate":"2029-12-31"},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":["RET-fusion Non Small Cell Lung Cancer","Lung Neoplasm","Carcinoma, Non-Small-Cell Lung","Respiratory Tract Neoplasms","Thoracic Neoplasms","Neoplasms by Site","Neoplasms","Lung Diseases","Respiratory Tract Disease","Carcinoma, Bronchogenic","Bronchial Diseases","Head and Neck Neoplasms","Adenocarcinoma","Carcinoma","Neoplasms by Histologic Type","Neoplasms, Germ Cell and Embryonal","Neoplasms, Nerve Tissue"],"enrollment":223,"completionDate":"2025-01-27"},{"nctId":"NCT07452601","phase":"PHASE2","title":"Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-25","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":90,"completionDate":"2028-12-30"},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":["Pancreatic Cancer"],"enrollment":84,"completionDate":"2028-12-31"},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":["Metastatic Breast Cancer"],"enrollment":541,"completionDate":"2028-07"},{"nctId":"NCT00616967","phase":"PHASE2","title":"Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-05","conditions":["Breast Cancer"],"enrollment":68,"completionDate":"2027-02"},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":["Metastatic Pancreatic Cancer"],"enrollment":162,"completionDate":"2027-10-30"},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":866,"completionDate":"2026-06-19"},{"nctId":"NCT07444541","phase":"PHASE1,PHASE2","title":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anova Innovation Limited","startDate":"2026-03","conditions":["Pancreatic Cancer"],"enrollment":84,"completionDate":"2028-12"},{"nctId":"NCT03652428","phase":"PHASE1,PHASE2","title":"Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2019-04-02","conditions":["Locally Advanced Pancreatic Cancer"],"enrollment":24,"completionDate":"2026-12-31"},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":["Solid Tumor"],"enrollment":681,"completionDate":"2027-12-31"},{"nctId":"NCT07438106","phase":"PHASE2","title":"A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02","conditions":["Locally Advanced Pancreatic Cancer With KRAS G12D Mutation"],"enrollment":30,"completionDate":"2027-12"},{"nctId":"NCT07049055","phase":"PHASE1,PHASE2","title":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","status":"RECRUITING","sponsor":"Engeneic Pty Limited","startDate":"2026-01-12","conditions":["Pancreatic Cancer, Metastatic","PDAC - Pancreatic Ductal Adenocarcinoma"],"enrollment":144,"completionDate":"2028-09"},{"nctId":"NCT06103864","phase":"PHASE3","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-23","conditions":["Breast Cancer"],"enrollment":625,"completionDate":"2030-09-30"},{"nctId":"NCT06452602","phase":"PHASE2","title":"Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-19","conditions":["Esophageal Cancer"],"enrollment":60,"completionDate":"2027-06-01"},{"nctId":"NCT06608927","phase":"PHASE3","title":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2024-12-13","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":610,"completionDate":"2030-11-30"},{"nctId":"NCT04104672","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2019-11-06","conditions":["Advanced Pancreatic Cancer"],"enrollment":196,"completionDate":"2027-05"},{"nctId":"NCT07437898","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study","status":"RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2024-09-03","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":42,"completionDate":"2026-12-01"},{"nctId":"NCT07436741","phase":"PHASE3","title":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02","conditions":["Pancreatic Cancer, Adult"],"enrollment":106,"completionDate":"2030-03"},{"nctId":"NCT07432594","phase":"PHASE2","title":"Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":["High-grade Serous Ovarian Cancer (HGSOC)","Fallopian Tube Cancers","Primary Peritoneal Cancer"],"enrollment":82,"completionDate":"2027-06-30"},{"nctId":"NCT07433673","phase":"PHASE2","title":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2026-08","conditions":["Colon and Rectal Cancer"],"enrollment":20,"completionDate":"2029-01"},{"nctId":"NCT06692738","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-18","conditions":["Non-small Cell Lung Cancer"],"enrollment":880,"completionDate":"2029-10-08"},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":330,"completionDate":"2028-09-09"},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":["Non-small Cell Lung Cancer"],"enrollment":673,"completionDate":"2026-01-26"},{"nctId":"NCT06449222","phase":"PHASE2","title":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-26","conditions":["Locally Advanced Breast Cancer","Triple Negative Breast Cancer","Metastatic Triple Negative Breast Cancers"],"enrollment":83,"completionDate":"2029-06"},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":["Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","Non-Small Cell Carcinoma of Lung, TNM Stage 4"],"enrollment":327,"completionDate":"2026-12-22"},{"nctId":"NCT04605913","phase":"PHASE1,PHASE2","title":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-01","conditions":["Pancreas Cancer","Metastatic Pancreatic Cancer","Pancreatic Adenocarcinoma","Metastatic Adenocarcinoma"],"enrollment":40,"completionDate":"2028-10-01"},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":["Breast Cancer"],"enrollment":72,"completionDate":"2028-02-01"},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":["Carcinoma, Squamous Cell, Non-small-cell Lung"],"enrollment":851,"completionDate":"2026-01-30"},{"nctId":"NCT07430579","phase":"NA","title":"Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The Second Hospital of Shandong University","startDate":"2024-12-09","conditions":["Pathological Complete Remission","Objective Response Rate","Immune-related Adverse Events","Quality of Life"],"enrollment":25,"completionDate":"2028-06-30"},{"nctId":"NCT06996782","phase":"PHASE1,PHASE2","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"enrollment":152,"completionDate":"2029-02-23"},{"nctId":"NCT02705196","phase":"PHASE1,PHASE2","title":"LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Lokon Pharma AB","startDate":"2016-11","conditions":["Pancreatic Cancer"],"enrollment":51,"completionDate":"2025-11-15"},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":["Carcinoma, Squamous Cell","Oral Cancer","Oropharynx Cancer","Larynx Cancer","Lip Cancer","Esophageal Cancer"],"enrollment":39,"completionDate":"2027-02-02"}],"_emaApprovals":[{"date":"2019-05-10","status":"Authorised","company":"TEVA BV"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"ABRAXANE"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","route":"INTRAVENOUS","productName":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound)"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"PACLITAXELPACLITAXEL"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Paclitaxel"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Paclitaxel"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148314","MMSL":"2296","NDDF":"004116","UNII":"P88XT4IS4D","VUID":"4020736","CHEBI":"CHEBI:45863","VANDF":"4020736","INN_ID":"7052","RXNORM":"196466","UMLSCUI":"C0144576","chemblId":"CHEMBL4303645","ChEMBL_ID":"CHEMBL428647","KEGG_DRUG":"D00491","DRUGBANK_ID":"DB01229","PDB_CHEM_ID":" TA1","PUBCHEM_CID":"36314","SNOMEDCT_US":"387374002","IUPHAR_LIGAND_ID":"2770","MESH_DESCRIPTOR_UI":"D017239"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1992-","companyName":"Hq Spclt Pharma","relationship":"Original Developer"},{"period":"2019","companyName":"Teva Bv","relationship":"EMA Licensee"},{"period":"2019","companyName":"Taiho Pharmaceutical Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"11.0 hours","clearance":"6.4 mL/min/kg","bioavailability":"6%","fractionUnbound":"0.12%","volumeOfDistribution":"3.0 L/kg"},"publicationCount":3066,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:02.229477+00","atcClassification":{"source":"DrugCentral","atcCode":"L01CD01","allCodes":["L01CD01","L01CD51"]},"biosimilarFilings":[],"originalDeveloper":"Hq Spclt Pharma","recentPublications":[{"date":"2026 Mar 19","pmid":"41900865","title":"Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial.","journal":"Pharmaceutics"},{"date":"2026 Mar 16","pmid":"41899178","title":"Chemotherapy for Older Adults with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.","journal":"Journal of clinical medicine"},{"date":"2026 Mar 27","pmid":"41896491","title":"Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study.","journal":"Journal of cancer research and clinical oncology"},{"date":"2026 Mar 17","pmid":"41892321","title":"Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer.","journal":"Cells"},{"date":"2026 Mar 27","pmid":"41891402","title":"Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring.","journal":"Cancer discovery"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"1992","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1992-12-29T00:00:00.000Z","mah":"HQ SPCLT PHARMA","brand_name_local":"TAXOL","application_number":"NDA020262"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2019-05-10T00:00:00.000Z","mah":"TEVA BV","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7923536","territory":"US","patent_type":null,"expiry_date":"2023-12-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8138229","territory":"US","patent_type":null,"expiry_date":"2023-12-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8314156","territory":"US","patent_type":null,"expiry_date":"2023-12-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8138229*PED","territory":"US","patent_type":null,"expiry_date":"2024-06-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8314156*PED","territory":"US","patent_type":null,"expiry_date":"2024-06-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7923536*PED","territory":"US","patent_type":null,"expiry_date":"2024-06-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7820788","territory":"US","patent_type":null,"expiry_date":"2024-10-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7820788*PED","territory":"US","patent_type":null,"expiry_date":"2025-04-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8268348","territory":"US","patent_type":null,"expiry_date":"2026-02-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9101543","territory":"US","patent_type":null,"expiry_date":"2026-02-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7758891","territory":"US","patent_type":null,"expiry_date":"2026-02-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8034375","territory":"US","patent_type":null,"expiry_date":"2026-08-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7758891*PED","territory":"US","patent_type":null,"expiry_date":"2026-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9101543*PED","territory":"US","patent_type":null,"expiry_date":"2026-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8268348*PED","territory":"US","patent_type":null,"expiry_date":"2026-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8034375*PED","territory":"US","patent_type":null,"expiry_date":"2027-02-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9597409","territory":"US","patent_type":null,"expiry_date":"2032-03-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9393318","territory":"US","patent_type":null,"expiry_date":"2032-03-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9597409*PED","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9393318*PED","territory":"US","patent_type":null,"expiry_date":"2032-09-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9511046","territory":"US","patent_type":null,"expiry_date":"2034-01-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9511046*PED","territory":"US","patent_type":null,"expiry_date":"2034-07-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":49,"withResults":15},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:45:21.788062+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}